ClinicalTrials.gg
CompletedNCT01493947ATTRACTUpdated Oct 28, 2015Results posted

CD5024 1% [Ivermectin 1%] Cream Versus Metronidazole 0.75% Cream in Papulopustular Rosacea (PPR) Study

A Phase 3 interventional study of Ivermectin 1% cream and Metronidazole 0.75% cream in Papulopustular Rosacea, sponsored by Galderma R&D. Completed at 60 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-10-28.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
962
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing ivermectin in Rosacea — none open to participants now, none under way, none of them phase 3. Ivermectin · Rosacea.

Enrollment
Largest of 11
962 · median 486
Started
2012
the only one that year
Phase 3
6 of 11
none open now
Registered
3rd of 11
by date
Lead sponsor
4 of 11
Galderma R&D

Among the 11 studies testing ivermectin in Rosacea, this one has the largest enrollment, is the only one that started in 2012, is one of 6 in phase 3, and was the 3rd registered.

Rosacea

233 studies on the registry are indexed under Rosacea; 22 are open to participants now.

Browse Rosacea studies →

Open to participants now

None of the 11 studies testing ivermectin in Rosacea is open now. The open studies under Rosacea, anywhere →

About ivermectin

Ivermectin: first FDA approval 1996 (STROMECTOL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 16 Rosacea studies recruiting now, 9 (56%) set no upper age limit and 6 (38%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing ivermectin in Rosacea as a file.
02

Study summary

Study objectives:

  • To compare efficacy and safety of Ivermectin 1% cream versus metronidazole 0.75% cream in subjects with papulopustular rosacea after 16-week topical treatment.
  • And to compare, for subjects initially successfully treated by 16 weeks treatment, Ivermectin 1 % cream versus metronidazole 0.75% cream during a 36-week extension period by assessing, the time of first relapse, the relapse rate, and the number of days free of treatment
03

Conditions studied

  • Papulopustular Rosacea

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with papulopustular rosacea scored 3 (moderate) or 4 (severe) according to the Investigator Global Assessment (IGA),
  • Subjects with at least 15 but not more than 70 inflammatory lesions (papules and pustules) on the face.

Exclusion criteria

Exclusion Criteria:

  • Subjects with particular forms of rosacea (rosacea conglobate, rosacea fulminant, isolated rhinophyma, isolated pustulosis of the chin) or other facial dermatoses that may be confounded with papulopustular rosacea, such as peri oral dermatitis, facial keratosis pilar, or seborrheic dermatitis and acne,
  • Subjects with rosacea with more than two nodules on the face.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
962 participants (actual)

Study arms

  • Experimental
    Ivermectin 1% cream

    Drug: Ivermectin 1% cream

  • Active comparator
    Metronidazole 0.75% cream

    Drug: Metronidazole 0.75% cream

Interventions

  • Ivermectin 1% cream applied once daily on the face during 16-week plus 36-week extension period.

    Also known as: Soolantra

  • Metronidazole 0.75% cream applied twice daily on the face during 16-week plus 36-week extension period.

    Also known as: Metronidazole

06

What researchers measure

Primary outcomes

  1. Percent Change in Inflammatory Lesions From Baseline to Week 16

    Efficacy of Ivermectin versus Metronidazole as determined by the percent change in inflammatory lesions after a 16-week treatment period

    Time frame: Baseline and Week 16

Other outcomes

  1. Time to Relapse

    Relapse define as time elapsed between Week 16 and first reoccurrence of Investigator Global assessement (IGA) at '2 (mild)' , '3 (moderate)' or '4 (severe)'.

    Time frame: Week 16 up to Week 52

07

Results

Posted Oct 28, 2015

Participant flow

Period A Efficacy and Safety Data
Participant flow — Period A Efficacy and Safety Data
MilestoneIvermectinMetronidazole 0.75% Cream
Started478484
Completed446456
Not completed3228
Period B Extension Period
Participant flow — Period B Extension Period
MilestoneIvermectinMetronidazole 0.75% Cream
Started399358
Completed366326
Not completed3332

Outcome measures

PrimaryPercent Change in Inflammatory Lesions From Baseline to Week 16

Efficacy of Ivermectin versus Metronidazole as determined by the percent change in inflammatory lesions after a 16-week treatment period

Time frame:
Baseline and Week 16
Reported as:
Mean · percentage of change
Percent Change in Inflammatory Lesions From Baseline to Week 16
percentage of changeIvermectinMetronidazole 0.75% Cream
Percent Change in Inflammatory Lesions From Baseline to Week 16-83 ± 26-73.7 ± 39.7
Other pre-specifiedTime to Relapse

Relapse define as time elapsed between Week 16 and first reoccurrence of Investigator Global assessement (IGA) at '2 (mild)' , '3 (moderate)' or '4 (severe)'.

Time frame:
Week 16 up to Week 52
Reported as:
Median · Median days to relapse
Time to Relapse
Median days to relapseCD5024Metronidazole 0.75% Cream
Time to Relapse115 (113 to 165)85 (85 to 113)

Adverse events

Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ivermectin 1% Cream Period A—8/478 (1.7%)101/478 (21.1%)
Metronidazole 0.75% Cream Period A—5/484 (1%)100/484 (20.7%)
Ivermectin 1% Cream Period B—10/399 (2.5%)110/399 (27.6%)
Metronidazole 0.75% Cream Period B—11/359 (3.1%)91/359 (25.3%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventIvermectin 1% Cream Period AMetronidazole 0.75% Cream Period AIvermectin 1% Cream Period BMetronidazole 0.75% Cream Period B
Hypertensive CrisisVascular disorders1/4780/4840/3992/359
Coronary Artery DiseaseCardiac disorders0/4781/4840/3991/359
Anal FistulaGastrointestinal disorders0/4780/4840/3991/359
ErysipelasInfections and infestations0/4780/4840/3991/359
ParonychiaInfections and infestations0/4780/4840/3991/359
Respiratory Tract Infection BacterialInfections and infestations0/4780/4840/3991/359
OsteoathritisMusculoskeletal and connective tissue disorders0/4780/4841/3991/359
Ischaemic StrokeNervous system disorders0/4780/4841/3991/359
Ectopic PregnancyPregnancy, puerperium and perinatal conditions0/4780/4840/3991/359
Colon CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/4780/4840/3991/359
Most frequent other events
Showing 10 of 18
Most frequent other events
EventIvermectin 1% Cream Period AMetronidazole 0.75% Cream Period AIvermectin 1% Cream Period BMetronidazole 0.75% Cream Period B
NasopharingitisInfections and infestations32/47829/48437/39939/359
HeadacheNervous system disorders15/47811/4845/3994/359
InfluenzaInfections and infestations9/47810/48412/3996/359
HypertensionVascular disorders6/4784/4844/3997/359
Oral HerpesInfections and infestations3/4785/4847/3993/359
PharyngitisInfections and infestations3/4784/4845/3996/359
Back PainMusculoskeletal and connective tissue disorders7/4784/4846/3995/359
Urinary Tract InfectionInfections and infestations0/4781/4842/3995/359
BronchitisInfections and infestations6/4784/4844/3993/359
Upper Respiratory Tract InfectionInfections and infestations6/4784/4841/3990/359

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)IvermectinMetronidazole 0.75% CreamTotal
<=18 years000
Between 18 and 65 years394398792
>=65 years8486170
Sex: Female, Male
Sex: Female, Male(Participants)IvermectinMetronidazole 0.75% CreamTotal
Female311316627
Male167168335
Region of Enrollment
Region of Enrollment(participants)IvermectinMetronidazole 0.75% CreamTotal
Czech Republic404080
Russian Federation393574
Romania5752109
Hungary7684160
Ukraine303060
Poland5757114
United Kingdom161935
Bulgaria201737
France313667
Germany112114226
08

Study locations

60 sites
  • Galderma Investigational Site
    Pleven, Bulgaria
  • Galderma Investigational Site
    Plovdiv, Bulgaria
  • Galderma Investigational Site
    Sofia, Bulgaria
  • Galderma Investigational Site
    Chomutov, Czech Republic
  • Galderma Investigational Site
    Hradec Kralove, Czech Republic
  • Galderma Invetigational site
    Olomouc, Czech Republic
  • Galderma Investigational Site
    Pardubice, Czech Republic
  • Galderma Investigational Site
    Praha 1, 110 00, Czech Republic
  • Galderma Investigational Site
    Slany, 27 401, Czech Republic
  • Galderma Investigational Site
    Bordeaux, France
  • Galderma Investigational Site
    Brest, France
  • Galderma Investigational Site
    Cannes, France
  • Galderma Investigational Site
    Nice, France
  • Galderma Investigational Site
    Saint Etienne, France
  • Galderma Investigational Site
    Augsburg, Germany
  • Galderma Investigational Site
    Berlin, 13 507, Germany
  • Galderma Investigational Site
    Bonn, Germany
  • Galderma Investigational Site
    Darmstadt, 64 297, Germany
  • Galderma Investigational Site
    Dresden, Germany
  • Galderma Investigational Site
    Hamburg, Germany
  • Galderma Investigational Site
    Langenau, 89 129, Germany
  • Galderma Investigational Site
    Mahlow, 15 831, Germany
  • Galderma Investigational Site
    Mainz, Germany
  • Galderma Investigational Site
    Munich, Germany
  • Galderma Investigational Site
    Munster, Germany
  • Galderma Investigational Site
    Tubingen, Germany
  • Galderma Investigational Site
    Wuppertal, Germany
  • Galderma Investigational Site
    Budapest, 052, Hungary
  • Galderma Investigational Site
    Budapest, 1135, Hungary
  • Galderma Investigational Site
    Budapest, 1238, Hungary
  • Galderma Investigational Site
    Budapest, Hungary
  • Galderma Investigational Site
    Debrecen, 4032, Hungary
  • Galderma Investigational Site
    Miskolc, Hungary
  • Galderma Investigational Site
    Pecel, 21 19, Hungary
  • Galderma Investigational Site
    Szeged, Hungary
  • Galderma Investigational Site
    Szekszard, Hungary
  • Galderma Investigational Site
    Szolnok, Hungary
  • Galderma Investigational Site
    Bialystok, Poland
  • Galderma Investigational Site
    Gdansk, Poland
  • Galderma Investigational Site
    Krakow, Poland
  • Galderma Investigational Site
    Warszawa, Poland
  • Galderma Investigational Site
    Wroclaw, Poland
  • Galderma Investigational Site
    Brasov, Romania
  • Galderma Investigational Site
    Bucharest, Romania
  • Galderma Investigational Site
    Craiova, Romania
  • Galderma Investigational Site
    Timisoara, Romania
  • Galderma Investigational Site
    Tirgu Mures, Romania
  • Galderma Investigational Site
    Chelyabinsk, Russian Federation
  • Galderma Investigational Site
    Lipetsk, Russian Federation
  • Galderma Investigational Site
    Moscow, Russian Federation
  • Galderma Investigational Site
    Nizhny Novgorod, Russian Federation
  • Galderma Investigational Site
    Dnipropetrovsk, Ukraine
  • Galderma Investigational Site
    Donetsk, Ukraine
  • Galderma Investigational Site
    Kiev, Ukraine
  • Galderma Investigational Site
    Lviv, Ukraine
  • Galderma Investigational Site
    Uzhgorod, Ukraine
  • Galderma Investigational Site
    Berkshire, United Kingdom
  • Galderma Investigational Site
    Bexhill, United Kingdom
  • Galderma Investigational Site
    London, United Kingdom
  • Galderma Investigational Site
    Nuneaton, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2015, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2011
First posted
Dec 16, 2011
Start
Apr 2012
Primary completionActual
Dec 2013
CompletionActual
Dec 2013
Results first posted
Oct 28, 2015
Last update
Oct 28, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01493947
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Dec 16, 2011
Start date
Apr 2012
Primary completion
Dec 2013
Completion
Dec 2013
Results posted
Oct 28, 2015
Last update
Oct 28, 2015

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivermectin

Start the discussion